Cargando…

Targeting CD38 for acute leukemia

Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn’t improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new treatments for R/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Xushu, Ma, Hongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597453/ https://www.ncbi.nlm.nih.gov/pubmed/36313735 http://dx.doi.org/10.3389/fonc.2022.1007783

Ejemplares similares

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
por: Prejzner, Witold, et al.
Publicado: (2023)

Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
por: Farber, Meike, et al.
Publicado: (2021)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

CD38: A Significant Regulator of Macrophage Function
por: Li, Wentao, et al.
Publicado: (2022)

Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
por: Barbosa, Karina, et al.
Publicado: (2023)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia
por: Murtadha, Mariam, et al.
Publicado: (2023)

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2016)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
por: Pousse, Laurène, et al.
Publicado: (2023)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2019)

Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia
por: Curran, Emily, et al.
Publicado: (2015)

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
por: Lu, Rui, et al.
Publicado: (2017)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

Downregulation of GNA15 Inhibits Cell Proliferation via P38 MAPK Pathway and Correlates with Prognosis of Adult Acute Myeloid Leukemia With Normal Karyotype
por: Li, Mengya, et al.
Publicado: (2021)

Methylation of SPRED1: A New Target in Acute Myeloid Leukemia
por: Su, Nan, et al.
Publicado: (2022)

Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia
por: Sun, Younguk, et al.
Publicado: (2018)

Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
por: Feng, Lili, et al.
Publicado: (2023)

The Differential Expression of CD47 may be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia
por: Yan, Xiao, et al.
Publicado: (2022)

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
por: Plesa, Adriana, et al.
Publicado: (2017)

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
por: Jiang, Zhiwu, et al.
Publicado: (2016)

The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis
por: Huang, Wanxue, et al.
Publicado: (2022)

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
por: Arriazu, Elena, et al.
Publicado: (2016)

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity
por: Lamble, Adam J., et al.
Publicado: (2018)

Opportunities and Challenges for Gut Microbiota in Acute Leukemia
por: Ma, Tao, et al.
Publicado: (2021)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

CD81 and Its Relationship to Treatment Response in Patients With Acute Myeloid Leukemia at a Hospital in Hanoi, Vietnam
por: Tuan Nguyen, Tung, et al.
Publicado: (2023)

Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
por: Tan, Shi Hao, et al.
Publicado: (2017)

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
por: Hoffman, Lindsey M., et al.
Publicado: (2014)

Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia
por: Magliulo, Daniela, et al.
Publicado: (2018)

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
por: Chapuis, Nicolas, et al.
Publicado: (2019)

Targeting the GFI1/1B—CoREST Complex in Acute Myeloid Leukemia
por: van Bergen, Maaike G. J. M., et al.
Publicado: (2019)

CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint
por: Ding, Zhuang, et al.
Publicado: (2021)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Research progress on molecular biomarkers of acute myeloid leukemia
por: Yin, Pei-Yuan, et al.
Publicado: (2023)

Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
por: Buono, Roberta, et al.
Publicado: (2023)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vgq4772lda8hpopmg7pcnboq0g